Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.720
-0.010 (-0.58%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Celularity Revenue
Celularity had revenue of $9.30M in the quarter ending September 30, 2024, with 145.54% growth. This brings the company's revenue in the last twelve months to $48.20M, up 225.94% year-over-year. In the year 2023, Celularity had annual revenue of $22.77M with 26.68% growth.
Revenue (ttm)
$48.20M
Revenue Growth
+225.94%
P/S Ratio
0.76
Revenue / Employee
$401,667
Employees
120
Market Cap
38.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CELU News
- 5 weeks ago - Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - GlobeNewsWire
- 5 weeks ago - Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - GlobeNewsWire
- 4 months ago - Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - GlobeNewsWire
- 4 months ago - Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 - GlobeNewsWire
- 4 months ago - Celularity Inc. Announces Receipt of Nasdaq Notification - GlobeNewsWire
- 4 months ago - Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific - GlobeNewsWire
- 5 months ago - Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - GlobeNewsWire
- 5 months ago - Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - GlobeNewsWire